

## The Implications of Recent Data Sets for the Management of Hepatocellular Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following overall survival (OS) outcomes was noted in the Phase III HIMALAYA study comparing the STRIDE regimen of tremelimumab with durvalumab to sorafenib in the treatment of advanced hepatocellular carcinoma (HCC)?
  - OS was superior with the STRIDE regimen
  - OS was superior with sorafenib
  - OS was equivalent between the 2 regimens
- Which of the following statements best describes the association between occurrence of immune-mediated adverse events (imAEs) and OS among patients who received durvalumab/tremelimumab in the Phase III HIMALAYA trial?
  - A detriment in OS was observed for participants who had an imAE in comparison to those who did not
  - An improvement in OS was observed for participants who had an imAE in comparison to those who did not
  - OS was similar between participants who had an imAE and those who did not
- Which of the following OS outcomes was observed among patients aged 65 or older with unresectable HCC treated with first-line tislelizumab compared to sorafenib on the Phase III RATIONALE trial?
  - Tislelizumab demonstrated inferior OS
  - Tislelizumab demonstrated comparable OS
  - Tislelizumab demonstrated superior OS
- A randomized Phase III trial evaluating camrelizumab in combination with rivoceranib versus sorafenib as first-line therapy for patients with unresectable HCC demonstrated a statistically significant improvement in which of the following endpoints with the combination regimen?
  - Progression-free survival
  - OS
  - Both a and b
  - Neither a nor b
- Patient-reported outcomes from the Phase III IMbrave050 trial evaluating adjuvant atezolizumab with bevacizumab versus active surveillance for patients with HCC at high risk of recurrence after procedures with curative intent demonstrated which of the following?
  - No clinically meaningful deterioration in health-related quality of life (HRQoL) or function
  - Clinically meaningful deterioration in HRQoL or function